DiagnoCure retains JMP Securities

DiagnoCure (TSX:CUR) has retained financial advisors JMP Securities to assist in determining the best option to drive the growth of its U.S.-based subsidiary, DiagnoCure Oncology Laboratories.

“We are very excited to be partnering with JMP, and we are confident that their expertise will help us determine the most effective method to roll out our colorectal cancer disease management program,” DiagnoCure Oncology president Valerie Palmieri said in a statement.

“Our CLIA, CAP and NY accredited laboratory is well positioned to move forward with this new business model,” she added.